European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
First New Osteoporosis Medicine Approved in the European Union (EU) Since 2010
Novel Bone-Builder With a Dual Effect That Increases Bone Formation and Reduces Bone Loss
THOUSAND OAKS, Calif. and BRUSSELS, Dec. 11, 2019 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regulatory Amgen, UCB, EVENITY, romosozumab, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news